Effects of castration on cannabinoid cb receptor expression and on the biological actions of cannabinoid in the parotid gland.
In the present study, we examined whether cannabinoid receptor expression and the effects of receptor stimulation vary as a function of gonadal status in a peripheral tissue, namely the male rat parotid gland. Four groups of male rats were studied: gonadal intact, castrated, castrated testosterone (1 mg/100 g bodyweight) treated and gonadal intact testosterone treated. 2. The results showed that the density of CB(1) receptors decreased after castration and that receptor density was restored to control values after testosterone treatment. This decrement was associated with a decrease of anandamide (10(-10) to 10(-5) mol/L)-induced cAMP accumulation and amylase release without changes in the anandamide-induced inhibition of Na(+)/K(+)-ATPase activity. 3. Castration did not modify either the subtype of cannabinoid receptor involved in the actions of anandamide or drug affinity for the receptor. 4. The mechanism underlying anandamide-induced cAMP accumulation, amylase release and inhibition of Na(+)/K(+)-ATPase activity, namely through the activation of adenylyl cyclase, was the same in control and castrated rats. 5. Basal cAMP accumulation, amylase release and Na(+)/K(+)-ATPase activity were not altered by castration. 6. Castration had no effect on the concentration of total protein. 7. It can be concluded that CB(1) cannabinoid receptor expression is regulated by testosterone in male rat parotid gland and this has functional implications for cAMP accumulation and amylase release.
School of Dentistry, University of Buenos Aires and Argentine National Research Council (CONICET), Buenos Aires, Argentina. lucila@farmaco.odon.uba.ar
Lucila
L
Busch
Leonor
L
Sterin-Borda
Enri
E
Borda
D000251:Adenosine Triphosphatases / Q000378:metabolism; D000262:Adenylyl Cyclases / Q000378:metabolism; D000681:Amylases / Q000378:metabolism; D000818:Animals; D001095:Arachidonic Acids / Q000494:pharmacology; D002186:Cannabinoids / Q000494:pharmacology*; D002462:Cell Membrane / Q000187:drug effects / Q000201:enzymology; D000242:Cyclic AMP / Q000378:metabolism; D063388:Endocannabinoids; D008024:Ligands; D008297:Male; D009919:Orchiectomy; D010306:Parotid Gland / Q000187:drug effects* / Q000378:metabolism; D010880:Piperidines / Q000494:pharmacology; D053284:Polyunsaturated Alkamides; D011506:Proteins / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology; D011869:Radioligand Assay; D051381:Rats; D017208:Rats, Wistar; D043884:Receptor, Cannabinoid, CB1 / Q000096:biosynthesis*; D000077285:Rimonabant; D000254:Sodium-Potassium-Exchanging ATPase / Q000378:metabolism; D013739:Testosterone / Q000097:blood
D001095:Arachidonic Acids; D002186:Cannabinoids; D063388:Endocannabinoids; D008024:Ligands; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011506:Proteins; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D013739:Testosterone; D000242:Cyclic AMP; D000681:Amylases; D000251:Adenosine Triphosphatases; D000262:Adenylyl Cyclases; D000254:Sodium-Potassium-Exchanging ATPase; D000077285:Rimonabant; C078814:anandamide